Navigation Links
Dosing for RVX-208 Phase 1a Clinical Study Completed
Date:4/22/2008

Phase 1a study objectives were met

TSX Exchange Symbol: RVX

CALGARY, April 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," declared Donald J. McCaffrey, President & CEO of Resverlogix. "As reported earlier this year the most remarkable results from this study continue to be the outstanding pharmacokinetics (drugability) of RVX-208. With these successful results in hand we are now planning for our Phase 1b/2a trial which, pending discussions and approval from the FDA, we expect to start later this year."

The primary objectives of the Phase 1a trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase 1a human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The Company has selected the dosages to be used in the 28-day Phase 1b/2a study.

"We are very pleased with these promising results which indicate that RVX-208 is a safe and well tolerated drug," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Medical Affairs of Resverlogix. "We are in the process of finalizing the tables, figures and legends for this past study." A review of the pharmacokinetic data was recently presented at the Arteriosclerosis, Thrombosis and Vascular Biology conference in Atlanta, GA.

About Cardiovascular Disease (CVD)

CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Immucor CEOs Italian Trial Moves Toward Second Phase
7. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
11. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... CAMBRIDGE, Mass. , April 21, 2015 ... clinical data from a multi-arm Phase 1 study of ... data were presented in an oral session by Dr. ... Association for Cancer Research Annual Meeting in ... and tolerability of MM-141 as a monotherapy and in ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... Calif. , April 21, 2015 /PRNewswire/ ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... announced that Dr. Mark W. Sawicki ... the 3rd Annual BioLogistics Summit in ...
(Date:4/21/2015)... Mass. , April 21, 2015 /PRNewswire/ ... developing transformative pharmaceutical products for subcutaneous delivery, ... pivotal trial of its investigational proprietary drug ... of edema associated with congestive heart failure. ... scPharmaceuticals is developing a proprietary patch pump.  ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3
... ET; 8:00 a.m. PT, VANCOUVER and SAN DIEGO, ... a clinical-stage developer of drugs for infectious,diseases, will host ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss ... 2008 and provide an update on,company activities. To participate ...
... on Detroit Area, DETROIT, March 11 ... its new study, Affordable Broadband:,Empowering Communities Across the ... to education, health care and civic,involvement in minority ... Empowerment Council (DEC) that was launched,earlier this year ...
... March 11 Haemonetics,Corporation announced today the appointment ... Chief Marketing Officer. In this position, Mr. Allen,will ... portfolio in addition to his current responsibilities as ... commented, "Pete Allen was an,architect of our strategic ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the next big innovation in sustainable climate technology? ... for Business Law and Regulation at Case Western Reserve ... do just that. "Technology-induced prizes have a long ... on a Climate Prize Rewarding Energy Innovation to Achieve ...
... ST. AUGUSTINE, TRINIDAD AND TOBAGOFlower color in plants ... carotenoids. Research has found that the ultimate color displayed ... also on other factors, including cell shape, presence of ... role of pH in creating color has allowed plant ...
... Ill. Researchers have identified a protein long known to ... growth. Their study, in the journal Oncogene , is ... accomplishes this feat. "People suggested that Runx3 might be ... it is down-regulated in a lot of breast cancer cell ...
Cached Biology News:CWRU law professor eyes prize-based incentives to generate climate innovation 2Engineering blue-hued flowers 2Team identifies new breast cancer tumor suppressor and how it works 2
... ( Abpromise for all tested ... Synthetic peptide derived from within residues ... MSY2/YBOX2. (Note: the amino acid ... (Peptide available as ab27460 .) ...
Request Info...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: